Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by Tekla Capital Management LLC
Tekla Capital Management LLC reduced its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 5.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 750,905 shares of the biopharmaceutical company’s stock after selling 45,000 shares during the quarter. Alexion Pharmaceuticals comprises approximately 3.4% of Tekla Capital Management LLC’s portfolio, making the stock its 9th biggest position. Tekla Capital Management LLC owned approximately 0.34% of Alexion Pharmaceuticals worth $91,363,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Commerzbank Aktiengesellschaft FI raised its position in Alexion Pharmaceuticals by 151.5% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after acquiring an additional 79,943 shares in the last quarter. Morgan Stanley raised its position in Alexion Pharmaceuticals by 112.0% in the first quarter. Morgan Stanley now owns 585,482 shares of the biopharmaceutical company’s stock worth $70,983,000 after acquiring an additional 309,299 shares in the last quarter. HPM Partners LLC raised its position in Alexion Pharmaceuticals by 267.2% in the second quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 4,861 shares in the last quarter. Principal Financial Group Inc. raised its position in Alexion Pharmaceuticals by 1.2% in the second quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock worth $40,823,000 after acquiring an additional 4,115 shares in the last quarter. Finally, LMR Partners LLP purchased a new position in Alexion Pharmaceuticals in the first quarter worth $927,000. 94.17% of the stock is owned by institutional investors and hedge funds.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded down 0.49% during midday trading on Thursday, hitting $138.77. The company had a trading volume of 529,186 shares. The firm has a market cap of $30.97 billion, a price-to-earnings ratio of 60.18 and a beta of 1.40. The company’s 50 day moving average is $139.14 and its 200 day moving average is $124.77. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.48. The company had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm’s revenue was up 21.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.13 EPS. Equities analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current fiscal year.
Several research analysts have issued reports on the company. UBS AG reiterated a “buy” rating and issued a $142.00 price objective (up previously from $140.00) on shares of Alexion Pharmaceuticals in a research report on Monday, June 26th. BidaskClub cut Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective for the company in a research report on Wednesday, August 2nd. Jefferies Group LLC set a $120.00 price objective on Alexion Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, June 8th. Finally, Leerink Swann reiterated a “buy” rating and issued a $182.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average price target of $157.21.
TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/28/alexion-pharmaceuticals-inc-alxn-shares-sold-by-tekla-capital-management-llc.html.
In related news, EVP Julie O’neill sold 11,160 shares of the stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares in the company, valued at approximately $3,738,560. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,070 shares of company stock valued at $2,416,869. 4.35% of the stock is currently owned by corporate insiders.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.